CN1195849C - April－具有生长效应的新的蛋白质 - Google Patents

April－具有生长效应的新的蛋白质 Download PDF

Info

Publication number
CN1195849C
CN1195849C CNB988090384A CN98809038A CN1195849C CN 1195849 C CN1195849 C CN 1195849C CN B988090384 A CNB988090384 A CN B988090384A CN 98809038 A CN98809038 A CN 98809038A CN 1195849 C CN1195849 C CN 1195849C
Authority
CN
China
Prior art keywords
april
cells
cell
dna
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988090384A
Other languages
English (en)
Chinese (zh)
Other versions
CN1270632A (zh
Inventor
J·茨乔普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apptek R&d Co
Original Assignee
Apptek R&d Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apptek R&d Co filed Critical Apptek R&d Co
Publication of CN1270632A publication Critical patent/CN1270632A/zh
Application granted granted Critical
Publication of CN1195849C publication Critical patent/CN1195849C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB988090384A 1997-09-12 1998-09-11 April－具有生长效应的新的蛋白质 Expired - Fee Related CN1195849C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US60/058,786 1997-09-12
US7938498P 1998-03-26 1998-03-26
US60/079,384 1998-03-26

Publications (2)

Publication Number Publication Date
CN1270632A CN1270632A (zh) 2000-10-18
CN1195849C true CN1195849C (zh) 2005-04-06

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988090384A Expired - Fee Related CN1195849C (zh) 1997-09-12 1998-09-11 April－具有生长效应的新的蛋白质

Country Status (20)

Country Link
US (3) US20030138884A1 (https=)
EP (1) EP1027431A2 (https=)
JP (1) JP2001515712A (https=)
KR (1) KR100618492B1 (https=)
CN (1) CN1195849C (https=)
AU (1) AU759717B2 (https=)
BR (1) BR9812634A (https=)
CA (1) CA2303615A1 (https=)
CZ (1) CZ294615B6 (https=)
EA (1) EA005411B1 (https=)
EE (1) EE200000147A (https=)
HU (1) HUP0004611A3 (https=)
IL (1) IL134537A0 (https=)
IS (1) IS5378A (https=)
NO (1) NO20001242L (https=)
NZ (1) NZ503850A (https=)
PL (1) PL339463A1 (https=)
SK (1) SK3542000A3 (https=)
TR (1) TR200000669T2 (https=)
WO (1) WO1999012965A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
JP2002516069A (ja) * 1997-09-30 2002-06-04 ファルマシア・アンド・アップジョン・カンパニー Ｔｎｆ関連死リガンド
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
BR0007719A (pt) 1999-01-25 2001-11-13 Biogen Inc Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
UA75049C2 (uk) * 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
JP2003521931A (ja) 2000-02-11 2003-07-22 バイオジェン インコーポレイテッド Ｔｎｆファミリーの異種ポリペプチド
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
CA2396793A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20020086018A1 (en) * 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
CA2413160A1 (en) * 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
JP2004537290A (ja) 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
AU2003207464A1 (en) 2002-01-04 2003-07-24 Xencor Dominant negative proteins and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
CA2554526A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
WO2006067210A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
AU2006278229B2 (en) 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
ATE500275T1 (de) 2005-09-26 2011-03-15 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
JP2009537563A (ja) 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
CA2919467C (en) 2009-03-02 2018-04-17 Jan Paul Medema Antibodies against a proliferating inducing ligand (april)
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
EP2542679A1 (en) * 2010-03-05 2013-01-09 Academisch Medisch Centrum bij de Universiteit van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
NL2011406C2 (en) * 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CN105592695B (zh) * 2013-09-23 2018-04-10 瑞泽恩制药公司 具有人源化信号调节蛋白基因的非人动物
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
SG10201811701YA (en) * 2013-11-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
US11484027B2 (en) 2020-10-29 2022-11-01 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
AU2022327178A1 (en) 2021-08-11 2024-03-28 Akso Biopharmaceutical, Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
JP2026510999A (ja) 2023-03-21 2026-04-10 バイオグラフ ５５，インク． Ｃｄ１９／ｃｄ３８多重特異性抗体
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
DK0897390T3 (da) * 1996-03-14 2004-03-08 Human Genome Sciences Inc Human tumornekrosefaktor-delta og -epsilon
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
JP2001515712A (ja) 2001-09-25
EA200000310A1 (ru) 2000-10-30
WO1999012965A2 (en) 1999-03-18
US20030138884A1 (en) 2003-07-24
TR200000669T2 (tr) 2000-08-21
EE200000147A (et) 2001-02-15
IL134537A0 (en) 2001-04-30
WO1999012965A3 (en) 1999-06-03
AU9316298A (en) 1999-03-29
NZ503850A (en) 2002-12-20
CA2303615A1 (en) 1999-03-18
CZ294615B6 (cs) 2005-02-16
HUP0004611A2 (hu) 2001-04-28
US20050112596A1 (en) 2005-05-26
CZ2000869A3 (cs) 2000-09-13
SK3542000A3 (en) 2000-08-14
CN1270632A (zh) 2000-10-18
EP1027431A2 (en) 2000-08-16
HUP0004611A3 (en) 2002-04-29
IS5378A (is) 2000-02-18
PL339463A1 (en) 2000-12-18
NO20001242L (no) 2000-05-11
BR9812634A (pt) 2000-08-22
EA005411B1 (ru) 2005-02-24
NO20001242D0 (no) 2000-03-09
KR100618492B1 (ko) 2006-08-31
KR20010023893A (ko) 2001-03-26
US20060084148A1 (en) 2006-04-20
AU759717B2 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
CN1195849C (zh) April－具有生长效应的新的蛋白质
CN1269832A (zh) K－配体－新的免疫系统蛋白
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
CN1342202A (zh) 可溶性受体br43×2和应用方法
CN1378595A (zh) 作为zalpha受体之配体的人细胞因子及其用途
US7087725B2 (en) Antibodies specifically reactive with a tumor necrosis factor related ligand
AU2004212622C1 (en) A Tumor Necrosis Factor Related Ligand
HK1025994B (en) A tumor necrosis factor related ligand
CZ2000867A3 (cs) Sekvence DNA kódující ligand Kay, způsob přípravy ligandu Kay a farmaceutický přípravek obsahující tento ligand

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee